Sarepta Therapeutics (SRPT) Projected to Post Quarterly Earnings on Wednesday

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) will likely be announcing its earnings results after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of $1.38 per share and revenue of $631.03 million for the quarter. Investors interested in registering for the company's conference call can do so using this link.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT traded down $2.13 during trading on Friday, reaching $106.28. The company's stock had a trading volume of 709,165 shares, compared to its average volume of 811,166. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The firm has a market capitalization of $10.15 billion, a price-to-earnings ratio of 85.02 and a beta of 0.75. Sarepta Therapeutics has a 12 month low of $101.15 and a 12 month high of $173.25. The firm has a 50 day moving average price of $117.88 and a 200 day moving average price of $123.85.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm's stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares of the company's stock, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of the firm's stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares of the company's stock, valued at $738,234. The trade was a 21.77 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.70% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on SRPT shares. Needham & Company LLC reissued a "buy" rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a report on Monday, January 27th. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and boosted their price objective for the company from $152.00 to $167.00 in a report on Thursday, November 7th. Guggenheim boosted their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a report on Thursday, November 7th. HC Wainwright reaffirmed a "sell" rating and set a $75.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 13th. Finally, Piper Sandler reduced their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $176.77.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.